Actualización y nuevos enfoques | 10 FEB 20

Tos crónica refractaria

La tos crónica refractaria es de difícil tratamiento. Se revisan los tratamientos actuales y las semejanzas con el dolor de tipo neuropático
Autor/a: Ryan N, Vertigan A, Birring S Fuente: Expert Opinion on Pharmacotherapy 19(7):687-711, May 2018 An update and systematic review on drug therapies for the treatment of refractory chronic cough
INDICE:  1. Página 1 | 2. Página 2
Página 2

References

1. Birring SS, Prudon B, Carr AJ, et al. Development of a symptom specific health status measure for patients with chronic cough: Leicester Cough Questionnaire (LCQ). Thorax. 2003;58:339–343.

2. Haque RA, Usmani OS, Barnes PJ. Chronic idiopathic cough: a discrete clinical entity? CHEST J. 2005;127:1710–1713.

3. Gibson P, Wang G, McGarvey L, et al. Treatment of unexplained chronic cough: CHEST guideline and expert panel report. CHEST J. 2016;149:27–44. • These recent cough guidelines recommend that speech pathology treatment or a trial of gabapentin be trialed for those patients with unexplained cough or to those that remain refractory to usual cough treatments.

4. Chung KF, Pavord ID. Prevalence, pathogenesis, and cause of chronic cough. Lancet. 2008;371:1364–1374.

5. Irwin RS, Boulet LP, Cloutier MM, et al. Managing cough as a defence mechanism and as a symptom. A consensus panel report of the American College of Chest Physicians. Chest. 1998;114:1269–1275.

6. Chung KF. Approach to chronic cough: the neuropathic basis for cough hypersensitivity syndrome. J Thorac Dis. 2014 Oct;6:S699–707.

7. Ryan NM, Gibson PG. Characterization of laryngeal dysfunction in chronic persistent cough. Laryngoscope. 2009;119:640–645. • Laryngeal dysfunction which manifests as paradoxical vocal cord movement and extrathoracic airway hyperresponsiveness is common in chronic cough. Laryngeal hypersensitivity is the common mechanism and it responds to speech pathology treatment.

8. Vertigan AE, Bone SL, Gibson PG. Laryngeal sensory dysfunction in laryngeal hypersensitivity syndrome. Respirology. 2013;18:948–956.

9. Gibson PG, Vertigan AE. Management of chronic refractory cough. BMJ. 2015;351:h5590.

10. Irwin RS, Rosen MJ, Braman SS. Cough. A comprehensive review. Arch Intern Med. 1977 Sep;137:1186–1191.

11. Kastelik J, Aziz I, Ojoo J, et al. Investigation and management of chronic cough using a probability-based algorithm. Eur Respir J. 2005;25:235–243.

12. Pratter MR, Brightlin CE, Boulet LP, et al. An empiric integrative approach to the management of cough. Chest. 2006;129:222S-231S.

13. Yu L, Qiu Z, Lue H, et al. Clinical benefit of sequential three-step empirical therapy in the management of chronic cough. Respirology. 2008;13:353–358.

14. Irwin RS, Baumann MH, Bolser DC, et al. Diagnosis and management of cough executive summary: ACCP evidence-based clinical practice guidelines. Chest. 2006;129:1S–23S.

15. Morice AH, Fontana GA, Belvisi MG, et al. ERS guidelines on the assessment of cough. Eur Respir J. 2007;29:1256–1276.

16. Morice AH, McGarvey L, Pavord I. British Thoracic Society Cough Guideline Group: recommendations for the management of cough in adults. Thorax. 2006;61:i1–i24.

17. Gibson PG, Chang AB, Glasgow NJ, et al. CICADA: cough in children and adults: diagnosis and assessment. Australian cough guidelines summary statement. Med J Aust. 2010;192:265–271. • CICADA is a clinical guideline for the assessment and management of persistent cough in children and adults developed by a multidisciplinary expert committee after a needs assessment by clinicians.

18. Chung KF. Chronic ‘cough hypersensitivity syndrome’: a more precise label for chronic cough. Pulm Pharmacol Ther. 2011;24:267–271.

19. Morice A, Faruqi S, Wright C, et al. Cough hypersensitivity syndrome: a distinct clinical entity. Lung. 2011;189:73–79. • The authors postulate that most patients with chronic cough have a single discrete clinical entity that they term ‘Cough 708 N. M. RYAN ET AL. Hypersensitivity Syndrome’. The unifying characteristic is afferent hypersensitivity and by regarding chronic cough as a single clinical entity it allows insight into the diagnosis, treatment, and future research of this characterized group of patients.

20. O’Neill J, McMahon SB, Undem BJ. Chronic cough and pain: Janus faces in sensory neurobiology? Pulm Pharmacol Ther. 2013 Oct;26:476–485.

21. Chung KF. Advances in mechanisms and management of chronic cough: The Ninth London International Cough Symposium 2016. Pulm Pharmacol Ther. 2017;47:2–8.

22. Mazzone SB, Cole LJ, Ando A, et al. Investigation of the neural control of cough and cough suppression in humans using functional brain imaging. J Neurosci. 2011;31:2948–2958. •• The authors provide novel insights into the supramedullary control of cough and cough suppression by using functional brain imaging in healthy humans with capsaicin-evoked cough. The data eloquently show the existence of distinct higher brain circuitry for facilitating and suppressing the cough reflex.

23. Morice AH, Millqvist E, Belvisi MG, et al. Expert opinion on the cough hypersensitivity syndrome in respiratory medicine. Eur Respir J. 2014;44:1132–1148.

24. Chung KF, McGarvey L, Mazzone SB. Chronic cough as a neuropathic disorder. Lancet Respir Med. 2013;1:414–422.

25. Lee B, Woo P. Chronic cough as a sign of laryngeal sensory neuropathy: diagnosis and treatment. Ann Otology Rhinology Laryngol. 2005;114:253–257.

26. Bastian RW, Vaidya AM, Delsupehe KG. Sensory neuropathic cough: a common and treatable cause of chronic cough. Otolaryngology —Head Neck Surgery. 2006;135:17–21.

27. Nilius B, Owsianik G, Voets T, et al. Transient receptor potential cation channels in disease. Physiol Rev. 2007;87:165–217.

28. Canning BJ, Chang AB, Bolser DC, et al. Anatomy and neurophysiology of cough: CHEST Guideline and Expert Panel report. Chest. 2014;146:1633–1648.

29. Groneberg DA, Niimi A, Dinh QT, et al. Increased expression of transient receptor potential vanilloid-1 in airway nerves of chronic cough. Am J Respir Crit Care Med. 2004 Dec 15;170:1276–1280.

30. Rami HK, Thompson M, Stemp G, et al. Discovery of SB-705498: a potent, selective and orally bioavailable TRPV1 antagonist suitable for clinical development. Bioorg Med Chem Lett. 2006 Jun 15;16:3287–3291.

31. Gavva NR, Bannon AW, Hovland DN Jr., et al. Repeated administration of vanilloid receptor TRPV1 antagonists attenuates hyperthermia elicited by TRPV1 blockade. J Pharmacol Exp Ther. 2007;323:128–137.

32. Khalid S, Murdoch R, Newlands A, et al. Transient receptor potential vanilloid 1 (TRPV1) antagonism in patients with refractory chronic cough: a double-blind randomized controlled trial. J Allergy Clin Immunol. 2014;134:56–62.

33. Duffy RA. Potential therapeutic targets for neurokinin-1 receptor antagonists. Expert Opin Emerg Drugs. 2004 May;9:9–21.

34. Hill R. NK1 (substance P) receptor antagonists–why are they not analgesic in humans? Trends Pharmacol Sci. 2000 Jul;21:244–246.

35. Dionne RA, Max MB, Gordon SM, et al. The substance P receptor antagonist CP-99,994 reduces acute postoperative pain. Clin Pharmacol Ther. 1998;64:562–568.

36. Urban LA, Fox AJ. NK1 receptor antagonists–are they really without effect in the pain clinic? Trends Pharmacol Sci. 2000 Dec;21:462–464.

37. Lee WS, Moussaoui SM, Moskowitz MA. Blockade by oral or parenteral RPR 100893 (a non-peptide NK1 receptor antagonist) of neurogenic plasma protein extravasation within guinea-pig dura mater and conjunctiva. Br J Pharmacol. 1994 Jul;112:920–924.

38. Moussaoui SM, Philippe L, Le Prado N, et al. Inhibition of neurogenic inflammation in the meninges by a non-peptide NK1 receptor antagonist, RP 67580. Eur J Pharmacol. 1993 Jul 20;238:421–424.

39. Shepheard SL, Williamson DJ, Williams J, et al. Comparison of the effects of sumatriptan and the NK1 antagonist CP-99,994 on plasma extravasation in Dura mater and c-fos mRNA expression in trigeminal nucleus caudalis of rats. Neuropharmacology. 1995;34:255–261.

40. El-Hashim AZ, Wyss D, Lewis C. Effect of a novel NK1 receptor selective antagonist (NKP608) on citric acid induced cough and airway obstruction. Pulm Pharmacol Ther. 2004;17:11–18.

41. Fahy JV, Wong HH, Geppetti P, et al. Effect of an NK1 receptor antagonist (CP-99,994) on hypertonic saline-induced bronchoconstriction and cough in male asthmatic subjects. Am J Respir Crit Care Med. 1995;152:879–884.

42. Smith JA, Allman D, Badri H, et al. The neurokinin-1 receptor antagonist orvepitant is a novel anti-tussive therapy for chronic refractory cough: results from a phase 2 study (VOLCANO-1). Am J Respir Crit Care Med. 2017;A2672 (Abstract).

43. Khakh BS, North RA. P2X receptors as cell-surface ATP sensors in health and disease. Nature. 2006 Aug 03;442:527–532.

44. Guile SD, Ince F, Ingall AH, et al. The medicinal chemistry of the P2 receptor family. Prog Med Chem. 2001;38:115–187.

45. Keystone EC, Wang MM, Layton M, et al. Clinical evaluation of the efficacy of the P2X7 purinergic receptor antagonist AZD9056 on the signs and symptoms of rheumatoid arthritis in patients with active disease despite treatment with methotrexate or sulphasalazine. Ann Rheum Dis. 2012;71:1630–1635.

46. Stock TC, Bloom BJ, Wei N, et al. Efficacy and safety of CE-224,535, an antagonist of P2X7 receptor, in treatment of patients with rheumatoid arthritis inadequately controlled by methotrexate. J Rheumatol. 2012;39:720–727.

47. Cockayne DA, Dunn PM, Zhong Y, et al. P2X(2) knockout mice and P2X(2)/P2X(3) double knockout mice reveal a role for the P2X(2) receptor subunit in mediating multiple sensory effects of ATP. J Physiol. 2005;567:621–639.

48. Prado FC, Araldi D, Vieira AS, et al. Neuronal P2X3 receptor activation is essential to the hyperalgesia induced by prostaglandins and sympathomimetic amines released during inflammation. Neuropharmacology. 2013;67:252–258.

49. Smith J, Kitt M, Butera P, et al. S27 The effect of P2X3 antagonism (AF–219) on experimentally evoked cough in healthy volunteers and chronic cough patients. Thorax. 2016;71:A17.1–A17.

50. Kamei J, Takahashi Y, Yoshikawa Y, et al. Involvement of P2X receptor subtypes in ATP-induced enhancement of the cough reflex sensitivity. Eur J Pharmacol. 2005;528:158–161.

51. Gibson PG, Ryan NM. Cough pharmacotherapy: current and future status. Expert Opin Pharmacother. 2011 Aug;12:1745–1755.

52. Finnerup NB, Attal N, Haroutounian S, et al. Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis. Lancet Neurol. 2015 Feb;14:162–173. • The authors provide an updated therapeutic algorithm for neuropathic pain based on GRADE resulting in changes to first-, second-, and third-line recommended treatments for neuropathic pain. Tricyclic antidepressants, pregabalin, gabapentin, gabapentin extended release or enacarbil, and duloxetine are first line based on strong GRADE recommendations for use. Lidnocaine patches are no longer first line because of weak quality of evidence. Strong opioids are now recommended as third line, primarily due to the potential risk of abuse.

53. Canning BJ, Mori N. Encoding of the cough reflex in anesthetized guinea pigs. Am J Physiol Regulatory, Integr Comp Physiol. 2011;300:R369–R377.

54. Keller JA, McGovern AE, Mazzone SB. Translating cough mechanisms into better cough suppressants. Chest. 2017;152:833–841.

55. Jarvis MF, Honore P, Shieh CC, et al. A-803467, a potent and selective Nav1.8 sodium channel blocker, attenuates neuropathic and inflammatory pain in the rat. Proc Natl Acad Sci USA. 2007 May 15;104:8520–8525.

56. Kemp MI. Structural trends among second-generation voltagegated sodium channel blockers. Prog Med Chem. 2010;49:81–111.

57. Scanio MJC, Shi L, Drizin I, et al. Discovery and biological evaluation of potent, selective, orally bioavailable, pyrazine-based blockers of the Nav1.8 sodium channel with efficacy in a model of neuropathic pain. Bioorg Med Chem. 2010;18:7816–7825. EXPERT OPINION ON PHARMACOTHERAPY 709

58. Song W-J, Chang Y-S, Faruqi S, et al. The global epidemiology of chronic cough in adults: a systematic review and meta-analysis. Eur Respir J. 2015 Letter;45:1479–1481. •• This is the first systematic analysis to estimate the epidemiological burden of chronic cough. There were inconsistencies in the existing literature suggesting an urgent need for global standardization. The high epidemiological burden of chronic cough further identified a major unmet clinical need.

59. Pollack A, Harrison C, Henderson J, et al. Neuropathic pain. Aust Fam Physician. 2013;42:91.

60. Colloca L, Ludman T, Bouhassira D, et al. Neuropathic pain. Nature Reviews Disease Primers. 2017;3:Article Number:17002.

 

Comentarios

Para ver los comentarios de sus colegas o para expresar su opinión debe ingresar con su cuenta de IntraMed.

AAIP RNBD
Términos y condiciones de uso | Política de privacidad | Todos los derechos reservados | Copyright 1997-2024